A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The legendary rocker is reuniting with original Sabbath guitarist Tony Iommi for the show at Premier League football club Aston Villla's stadium in their home city of Birmingham on July 5.

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Anthony Quinn, 49 and from Pity Me, has now been given a groundbreaking new treatment called Produodopa. Anthony becomes one of the first people in England to receive this outside of specialist ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the ...

Ozzy Osbourne is putting an end to the run.The rockstar is preparing for his final live performance, reuniting with Black ...

Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company that InvestingPro data shows maintains ...